Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746239 · ClinicalTrials.gov registry record · NA
Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety
A NA study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT00746239 is a NA study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT00746239, a NA study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
Almost 80% of panic disorder patients report difficulty sleeping. Sleep disturbances in turn may exacerbate underlying anxiety/panic attacks. Moreover, individuals with insomnia (sleep disturbance) are at higher risk of developing a new anxiety disorder. Therefore it is expected that improving sleep quality with medications along with other medications to treat anxiety component of panic disorder might be helpful. However, there is lack of pharmacological studies examining the effects of improving sleep disturbances with medications in panic disorder patients, which is a critical problem for providing optimal care to these patients. The objective of this proposal is to determine the effects of ramelteon (FDA approved for insomnia) on sleep disturbances in Panic disorder patients who are on escitalopram for underlying anxiety.
Interventions
- DRUG Placebo and Escitalopram
- DRUG Ramelteon and Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00746239
The ClinicalTrials.gov registry entry for NCT00746239 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo and Escitalopram is the first listed.
NCT00746239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00746239 about?
NCT00746239 is a clinical study titled "Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety". Almost 80% of panic disorder patients report difficulty sleeping. Sleep disturbances in turn may exacerbate underlying anxiety/panic attacks. Moreover, individuals with insomnia (sleep disturbance) are at higher risk of developing a new anxiety disorder. Therefore it is expected that improving sleep...
What is the current status of trial NCT00746239?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2008-08. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00746239?
The interventions under investigation include: Placebo and Escitalopram (DRUG), Ramelteon and Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00746239?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.